Herrera-Olivares W, González-Ramírez MF, Flores-Encarnación E

Language: Spanish
References: 21
Page: 185-191
PDF size: 594.23 Kb.

ABSTRACT

POEMS syndrome is a rare clinical entity with multisystem condition, resulting from an alteration of the plasma cells. The diagnostic criteria have evolved steadily and now must depend on the demonstration of a monoclonal gammopathy and peripheral neuropathy, it is necessary to add other clinical and/or biochemical and radiological data to complete the diagnosis. Likewise, the treatment has evolved similarly to other plasma cell dyscrasias, so more evidence are needed to standardize the treatment. The case of a patient in the fifth decade of life only debuting thrombocytosis is presented, subsequently added other clinical characteristics and could accurately establish the diagnosis. She was treated in the conventional manner, with a favorable outcome.

REFERENCES

1. Dispenzieri A. POEMS syndrome. Definitions and long-term outcome. Blood 2003;101:2496-2506.

2. Briani C. Polyneuropathy, Organomegaly, Endocrinopathy, M protein, Skin changes: not always a POEMS syndrome. Haematologica 2006;91:(2)e32.

3. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:592–601.

4. Li J, Zhou D. New advances in the diagnosis and treatment of POEMS syndrome. British Journal of Haematology 2013;161:303–315.

5. Guitard J, Pillet A, Soubrier M. Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome refractory to complete serum vascular endothelial growth factor (VEGF) blockade: insights from sequential VEGF monitoring. NDT Plus 2009;2:357–359.

6. Méndez-Herrera CR, Cordoví-Rodríguez D. Síndrome POEMS: revisión de la bibliografía. Rev Neurol 2011;53:44- 50.

7. Dispenzieri A, Buadi FK. A Review of POEMS Syndrome. Oncology Journal, Hematologic malignancies 2013(27).

8. Hurtado HM, Medina SC. Síndrome de POEMS, una entidad poliglandular poco conocida. Descripción de 3 casos. Endocrinol Nutr 2007;54(6):331-4.

9. Gandhi GY, Basu R, Dispenzieri A. Endocrinopathy in POEMS Syndrome: The Mayo Clinic Experience. Mayo Clin Proc 2007;82(7):836-842.

10. Barete S, Mouawad R, Choquet S. Skin Manifestations and Vascular endothelial Growth Factor Levels in POEMS syndrome. Arch Dermatol 2010;146(6):615-623.

11. Li J et al. Pulmonary hypertension in POEMS syndrome. Haematologica 2013;98(3):393-398.

12. Cui R, Yu S, Huang X. Papilloedema is an independent prognostic factor for POEMS syndrome. J Neurol 2014;261:60–65.

13. Dao LN, Hanson CA, Dispenzieri A. Bone marrow histopathology in POEMS syndrome: A distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 2011;117(24):6438-6444.

14. Sinués EM, Martínez-García R. Síndrome de POEMS: a propósito de un caso. Radiología 2009;51(4):424–427.

15. Li J et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS síndrome. Blood 2011;117(24):6445-6449.

16. Jouve P, HUmbert M, Chauveheid MP. POEMS syndromerelated pulmonary hypertension is steroid-responsive. Respiratory Medicine 2007;101:353–355.

17. Kayguzus I, Tezcan H. Bortezomib: a new therapeutic option for POEMS syndrome. European Journal of Haematology 2009;84:175–177.

18. Tomas JF, Giraldo P, Lecumberri R, and Nistal S. POEMS syndrome with severe neurological damage clinically recovered with Lenalidomide. Haematologica 2011;96:3324.

19. D´Souza A, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 2012;120(1):56-62.

20. Sekiguchi Y, Misawa S, Shibuya K. Ambiguous effects of anti- VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry 2013;84(12):1346-8.

21. Humeniuk MS, Gertz MA, Lacy MQ. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood 2013;122(1):68-73.